Biopharmaceutical firm Urovant Sciences announced that it has licensed global rights for the development and commercialisation of hMaxi-K, a novel investigational gene therapy for the treatment of overactive bladder (OAB). The company will study the potential of hMaxi-K as a treatment for patients with OAB symptoms for whom oral pharmacologic therapy has not been successful. “Over the past decade, there have been numerous clinical trials in which we have shown significant improvement in patient outcomes,” said Dr. David M. Goldstein, CEO of Urovant.
Biopharmaceutical firm Urovant Sciences announced that it has licensed global rights for the development and commercialisation of hMaxi-K, a novel investigational gene therapy for the treatment of overactive bladder (OAB). The company will study the potential of hMaxi-K as a treatment for patients with OAB symptoms for whom oral pharmacologic therapy has not been successful. It expects to initiate the Phase 2 hMaxi-K study next year.